Switch theme
Sign up to access all valuation multiples
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
1870
13.5K+
LTM Revenue $3.9B
LTM EBITDA $1.1B
$19.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sartorius has a last 12-month revenue (LTM) of $3.9B and a last 12-month EBITDA of $1.1B.
In the most recent fiscal year, Sartorius achieved revenue of $3.8B and an EBITDA of $884M.
Sartorius expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sartorius valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.9B | XXX | $3.8B | XXX | XXX | XXX |
| Gross Profit | $1.8B | XXX | $1.7B | XXX | XXX | XXX |
| Gross Margin | 47% | XXX | 45% | XXX | XXX | XXX |
| EBITDA | $1.1B | XXX | $884M | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 23% | XXX | XXX | XXX |
| EBIT | $680M | XXX | $491M | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $183M | XXX | $94.4M | XXX | XXX | XXX |
| Net Margin | 5% | XXX | 2% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $4.0B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Sartorius's stock price is EUR 197 (or $221).
Sartorius has current market cap of EUR 13.6B (or $15.3B), and EV of EUR 17.3B (or $19.5B).
See Sartorius trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $19.5B | $15.3B | XXX | XXX | XXX | XXX | $5.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Sartorius has market cap of $15.3B and EV of $19.5B.
Sartorius's trades at 5.1x EV/Revenue multiple, and 22.0x EV/EBITDA.
Equity research analysts estimate Sartorius's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sartorius has a P/E ratio of 83.2x.
See valuation multiples for Sartorius and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $15.3B | XXX | $15.3B | XXX | XXX | XXX |
| EV (current) | $19.5B | XXX | $19.5B | XXX | XXX | XXX |
| EV/Revenue | 5.0x | XXX | 5.1x | XXX | XXX | XXX |
| EV/EBITDA | 17.5x | XXX | 22.0x | XXX | XXX | XXX |
| EV/EBIT | 28.6x | XXX | 39.6x | XXX | XXX | XXX |
| EV/Gross Profit | 10.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 83.2x | XXX | 161.6x | XXX | XXX | XXX |
| EV/FCF | 50.1x | XXX | 30.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSartorius's last 12 month revenue growth is 8%
Sartorius's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Sartorius's rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sartorius's rule of X is 47% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sartorius and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | 10% | XXX | XXX | XXX |
| Rule of 40 | 33% | XXX | 31% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 47% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 20% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 32% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sartorius acquired XXX companies to date.
Last acquisition by Sartorius was XXXXXXXX, XXXXX XXXXX XXXXXX . Sartorius acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sartorius founded? | Sartorius was founded in 1870. |
| Where is Sartorius headquartered? | Sartorius is headquartered in Germany. |
| How many employees does Sartorius have? | As of today, Sartorius has 13.5K+ employees. |
| Is Sartorius publicy listed? | Yes, Sartorius is a public company listed on ETR. |
| What is the stock symbol of Sartorius? | Sartorius trades under SRT ticker. |
| When did Sartorius go public? | Sartorius went public in 1990. |
| Who are competitors of Sartorius? | Similar companies to Sartorius include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Sartorius? | Sartorius's current market cap is $15.3B |
| What is the current revenue of Sartorius? | Sartorius's last 12 months revenue is $3.9B. |
| What is the current revenue growth of Sartorius? | Sartorius revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Sartorius? | Current revenue multiple of Sartorius is 5.0x. |
| Is Sartorius profitable? | Yes, Sartorius is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sartorius? | Sartorius's last 12 months EBITDA is $1.1B. |
| What is Sartorius's EBITDA margin? | Sartorius's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of Sartorius? | Current EBITDA multiple of Sartorius is 17.5x. |
| What is the current FCF of Sartorius? | Sartorius's last 12 months FCF is $389M. |
| What is Sartorius's FCF margin? | Sartorius's last 12 months FCF margin is 10%. |
| What is the current EV/FCF multiple of Sartorius? | Current FCF multiple of Sartorius is 50.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
